美国 · 平台与数据 · Briefing.com

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

来源：Briefing.com · 美国 14 天前

Vaxcyte (PCVX) is soaring today after announcing topline results from the pivotal Phase 3 OPUS-1 trial evaluating VAX-31. VAX-31 is PCVX's investigational 31-valent pneumococcal…

在 Briefing.com 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.briefing.com)

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

推荐阅读

eToro Group (NASDAQ:ETOR) Sets New 52-Week Low on Analyst Downgrade

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

One of this year’s most important relationships in global financial markets is falling apart

Anthropic is AI trade's last big hope for a major IPO this year

Cadence Design Systems stock may move 6.2% on earnings

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

分享

推荐阅读

eToro Group (NASDAQ:ETOR) Sets New 52-Week Low on Analyst Downgrade

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

One of this year’s most important relationships in global financial markets is falling apart

Anthropic is AI trade's last big hope for a major IPO this year

Cadence Design Systems stock may move 6.2% on earnings